Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.26
MNK's Cash to Debt is ranked lower than
85% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MNK: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
MNK' s 10-Year Cash to Debt Range
Min: 0.15  Med: 0.30 Max: N/A
Current: 0.26
Equity to Asset 0.41
MNK's Equity to Asset is ranked lower than
80% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MNK: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MNK' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.36 Max: 0.41
Current: 0.41
0.25
0.41
Z-Score: 1.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4.30
MNK's Operating margin (%) is ranked lower than
78% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. MNK: -4.30 )
Ranked among companies with meaningful Operating margin (%) only.
MNK' s 10-Year Operating margin (%) Range
Min: -11.18  Med: 9.01 Max: 11.91
Current: -4.3
-11.18
11.91
Net-margin (%) -5.75
MNK's Net-margin (%) is ranked lower than
78% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. MNK: -5.75 )
Ranked among companies with meaningful Net-margin (%) only.
MNK' s 10-Year Net-margin (%) Range
Min: -12.57  Med: 4.61 Max: 7.45
Current: -5.75
-12.57
7.45
ROE (%) -5.17
MNK's ROE (%) is ranked lower than
74% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. MNK: -5.17 )
Ranked among companies with meaningful ROE (%) only.
MNK' s 10-Year ROE (%) Range
Min: -10.28  Med: -0.46 Max: 9.37
Current: -5.17
-10.28
9.37
ROA (%) -1.88
MNK's ROA (%) is ranked lower than
71% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MNK: -1.88 )
Ranked among companies with meaningful ROA (%) only.
MNK' s 10-Year ROA (%) Range
Min: -3.89  Med: -0.29 Max: 3.31
Current: -1.88
-3.89
3.31
ROC (Joel Greenblatt) (%) -8.37
MNK's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. MNK: -8.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.12  Med: 0.12 Max: 19.35
Current: -8.37
-19.12
19.35
» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNK Guru Trades in Q2 2014

Richard Perry 134,322 sh (New)
Paul Singer 916,000 sh (New)
Mario Gabelli 2,656 sh (New)
Chase Coleman 729,373 sh (New)
Jana Partners 5,725,711 sh (+75.22%)
John Paulson 6,724,800 sh (+19.30%)
John Paulson 6,724,800 sh (+19.30%)
First Eagle Investment 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
Q3 2014

MNK Guru Trades in Q3 2014

John Hussman 67,275 sh (New)
Chuck Royce 23,407 sh (New)
Steven Cohen 31,900 sh (New)
Joel Greenblatt 115,541 sh (New)
Richard Perry 1,150,000 sh (+756.15%)
Mario Gabelli 7,134 sh (+168.60%)
Jim Simons 359,502 sh (+50.48%)
John Paulson 9,000,000 sh (+33.83%)
First Eagle Investment 187 sh (unchged)
Pioneer Investments 120,582 sh (unchged)
Jana Partners Sold Out
Paul Singer Sold Out
Chase Coleman Sold Out
Paul Tudor Jones 24,849 sh (-91.96%)
» More
Q4 2014

MNK Guru Trades in Q4 2014

RS Investment Management 34,500 sh (New)
Louis Moore Bacon 14,363 sh (New)
Pioneer Investments 1,418,356 sh (+1076.26%)
Mario Gabelli 7,922 sh (+11.05%)
John Paulson 9,012,293 sh (+0.14%)
First Eagle Investment 187 sh (unchged)
John Hussman 67,275 sh (unchged)
Chuck Royce Sold Out
Richard Perry Sold Out
Steven Cohen 31,700 sh (-0.63%)
Joel Greenblatt 110,019 sh (-4.78%)
Jim Simons 117,502 sh (-67.32%)
Paul Tudor Jones 2,184 sh (-91.21%)
» More
Q1 2015

MNK Guru Trades in Q1 2015

Andreas Halvorsen 3,537,330 sh (New)
Jeremy Grantham 2,200 sh (New)
Paul Tudor Jones 28,384 sh (+1199.63%)
Pioneer Investments 1,454,418 sh (+2.54%)
First Eagle Investment 187 sh (unchged)
RS Investment Management 34,500 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
John Paulson 8,460,293 sh (-6.12%)
Mario Gabelli 7,122 sh (-10.10%)
Louis Moore Bacon 10,401 sh (-27.58%)
Joel Greenblatt 64,775 sh (-41.12%)
John Hussman 25,000 sh (-62.84%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 25.13
MNK's Forward P/E is ranked lower than
54% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. MNK: 25.13 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.70
MNK's P/B is ranked higher than
62% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MNK: 2.70 )
Ranked among companies with meaningful P/B only.
MNK' s 10-Year P/B Range
Min: 1  Med: 2.56 Max: 3.59
Current: 2.7
1
3.59
P/S 3.49
MNK's P/S is ranked higher than
51% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. MNK: 3.49 )
Ranked among companies with meaningful P/S only.
MNK' s 10-Year P/S Range
Min: 1.11  Med: 1.92 Max: 3.71
Current: 3.49
1.11
3.71
PFCF 26.72
MNK's PFCF is ranked higher than
69% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. MNK: 26.72 )
Ranked among companies with meaningful PFCF only.
MNK' s 10-Year PFCF Range
Min: 18.94  Med: 26.39 Max: 45.83
Current: 26.72
18.94
45.83
POCF 19.86
MNK's POCF is ranked higher than
67% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. MNK: 19.86 )
Ranked among companies with meaningful POCF only.
MNK' s 10-Year POCF Range
Min: 12.38  Med: 16.82 Max: 45.83
Current: 19.86
12.38
45.83
EV-to-EBIT -131.43
MNK's EV-to-EBIT is ranked lower than
178% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. MNK: -131.43 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s 10-Year EV-to-EBIT Range
Min: -133.3  Med: 21.80 Max: 52.1
Current: -131.43
-133.3
52.1
Current Ratio 2.86
MNK's Current Ratio is ranked higher than
59% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MNK: 2.86 )
Ranked among companies with meaningful Current Ratio only.
MNK' s 10-Year Current Ratio Range
Min: 2.29  Med: 2.56 Max: 2.86
Current: 2.86
2.29
2.86
Quick Ratio 2.41
MNK's Quick Ratio is ranked higher than
63% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MNK: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s 10-Year Quick Ratio Range
Min: 1.5  Med: 1.88 Max: 2.41
Current: 2.41
1.5
2.41
Days Inventory 88.95
MNK's Days Inventory is ranked higher than
63% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. MNK: 88.95 )
Ranked among companies with meaningful Days Inventory only.
MNK' s 10-Year Days Inventory Range
Min: 62.36  Med: 85.75 Max: 109.13
Current: 88.95
62.36
109.13
Days Sales Outstanding 63.06
MNK's Days Sales Outstanding is ranked higher than
58% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. MNK: 63.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s 10-Year Days Sales Outstanding Range
Min: 66.36  Med: 72.38 Max: 78.39
Current: 63.06
66.36
78.39

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.74
MNK's Price/Median PS Value is ranked lower than
65% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MNK: 1.74 )
Ranked among companies with meaningful Price/Median PS Value only.
MNK' s 10-Year Price/Median PS Value Range
Min: 0.6  Med: 0.97 Max: 1.85
Current: 1.74
0.6
1.85
Earnings Yield (Greenblatt) (%) -0.78
MNK's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MNK: -0.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.81  Med: 4.05 Max: 5
Current: -0.78
-0.81
5

Analyst Estimate

Sep15 Sep16 Sep17 Sep18
Revenue(Mil) 3,755 4,037 4,352 4,645
EPS($) 7.46 4.75 9.90 10.80
EPS without NRI($) 7.46 4.75 9.90 10.80

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 

More From Other Websites
Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg Jun 29 2015
Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg Jun 29 2015
MEDIA-Hikma, Mallinckrodt said to bid for Boehringer's Roxane Labs - Bloomberg Jun 29 2015
Hikma, Mallinckrodt Said to Bid for Boehringer’s Roxane Labs Jun 29 2015
MALLINCKRODT PLC Files SEC form 8-K/A, Financial Statements and Exhibits Jun 29 2015
Mallinckrodt Rebuilding Pattern After Sell Signal Jun 19 2015
MALLINCKRODT PLC Files SEC form 8-K, Other Events Jun 18 2015
Mallinckrodt’s Questcor Said Facing Multistate Antitrust Probe Jun 17 2015
Edited Transcript of MNK presentation 10-Jun-15 9:40pm GMT Jun 11 2015
Sharp Rally Sends These Spotlight Stocks To New Highs Jun 10 2015
Cramer Remix: When to buy Rite Aid's stock Jun 05 2015
Cramer: Serial acquirers raking in major dough Jun 05 2015
Cramer's favorite healthcare roll-ups Jun 05 2015
Top Mutual Funds Add To Medical Holdings Jun 02 2015
Top Drug Stock: Acquisitions Drive Mallinckrodt's Success May 29 2015
Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference May 27 2015
Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference May 27 2015
Mallinckrodt Extends Deadline For 2015 Research Fellowship Program May 26 2015
Mallinckrodt Extends Deadline For 2015 Research Fellowship Program May 26 2015
Mallinckrodt: Ofirmev, Acthar And A Nearby Buy Point May 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK